News summaryBenzingaNov 5, 2026, 12:00 PM
ADMA Biologics CEO Says Star Drug ASCENIV Is Just Getting Started
ADMA Biologics stock surges 23% after beating Q3 2026 earnings, led by a 31% rise in ASCENIV demand and strong margins.
Loading...
ADMA Biologics stock surges 23% after beating Q3 2026 earnings, led by a 31% rise in ASCENIV demand and strong margins.